/ICCM
ICCM Stock - IceCure Medical Ltd
Healthcare|Medical - DevicesNASDAQ
$0.67+1.92%
+$0.01 (+1.92%) • Dec 19
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.29
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+252.6%upside
Target: $2.38
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ICCM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.67 – $0.68
TARGET (TP)$2.38
STOP LOSS$0.62
RISK/REWARD1:31.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.26
52W High$1.66
52W Low$0.59
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.29M | $3.23M | $3.08M | $4.14M | $4.08M |
| Gross Profit | $1.45M | $1.30M | $1.45M | $2.19M | $2.66M |
| Gross Margin | 44.1% | 40.3% | 46.8% | 53.0% | 65.1% |
| Operating Income | $-15,696,000 | $-15,576,000 | $-16,739,000 | $-9,724,000 | $-4,361,617.764 |
| Net Income | $-15,318,000 | $-14,652,000 | $-17,217,000 | $-10,066,000 | $-4,777,098.786 |
| Net Margin | -465.5% | -453.8% | -558.1% | -243.3% | -117.0% |
| EPS | $-0.30 | $-0.32 | $-0.47 | $-0.35 | $-0.28 |
Company Overview
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ICCMBeat Rate
38%
Last 13 quarters
Avg Surprise
+2.1%
EPS vs Estimate
Beats / Misses
5/3
5 met exactly
Latest EPS
$-0.06
Q4 2025
EPS Surprise History
Q2 24
+14.3%
$-0.06vs$-0.07
Q2 24
0.0%
$-0.08vs$-0.08
Q3 24
+14.3%
$-0.06vs$-0.07
Q4 24
-14.3%
$-0.08vs$-0.07
Q1 25
-14.3%
$-0.08vs$-0.07
Q2 25
+25.0%
$-0.06vs$-0.08
Q3 25
0.0%
$-0.06vs$-0.06
Q4 25
-20.0%
$-0.06vs$-0.05
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.04 | — | — | — |
Q4 2025 | Nov 19, 2025 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.06 | $-0.06 | 0.0% | = MET |
Q2 2025 | May 28, 2025 | $-0.08 | $-0.06 | +25.0% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q4 2024 | Nov 26, 2024 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q3 2024 | Aug 20, 2024 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q2 2024 | May 28, 2024 | $-0.08 | $-0.08 | 0.0% | = MET |
Q2 2024 | Apr 3, 2024 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q4 2023 | Nov 15, 2023 | $-0.09 | $-0.09 | 0.0% | = MET |
Q3 2023 | Aug 14, 2023 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q2 2023 | May 22, 2023 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q1 2023 | Mar 29, 2023 | — | $-0.11 | — | — |
Q4 2022 | Dec 5, 2022 | $-0.11 | $-0.11 | 0.0% | = MET |
Q3 2022 | Aug 15, 2022 | $-0.12 | $-0.12 | 0.0% | = MET |
Q2 2022 | May 18, 2022 | — | $-0.12 | — | — |
Q2 2022 | Apr 1, 2022 | — | $-0.10 | — | — |
Q4 2021 | Nov 23, 2021 | — | $-0.09 | — | — |
Q3 2021 | Sep 23, 2021 | — | $-0.09 | — | — |
Q2 2021 | Apr 12, 2021 | — | $-0.07 | — | — |
Latest News
IceCure Medical shares are trading higher after the company announced that it expects a significant increase in Q4 sales in North America following the recent FDA clearance of ProSense Cryoablation for low-risk breast cancer.
📈 PositiveBenzinga•Dec 17, 2025, 05:23 PM
IceCure Medical Expects To Report Higher Q4 Sales In North America Compared To Last Year
📈 PositiveBenzinga•Dec 17, 2025, 01:46 PM
IceCure Medical Highlights Presentation Of Breast Cancer Studies Featuring ProSense Cryoablation
📈 PositiveBenzinga•Dec 10, 2025, 01:33 PM
IceCure Receives Notice Of Patent Allowance From China National Intellectual Property Administration Titled 'Cryogen Flow Control'
📈 PositiveBenzinga•Dec 5, 2025, 01:36 PM
CORRECTION: Icecure Medical Q3 EPS $(0.06) Misses $(0.05) Estimate, Sales $850.000K Beat $714.000K Estimate
➖ NeutralBenzinga•Nov 19, 2025, 02:14 PM
IceCure Medical Receives Registration, Approval For Its ProSense System For Distribution By Swissmedic
📈 PositiveBenzinga•Nov 18, 2025, 01:45 PM
IceCure Medical Receives Nasdaq Delisting Notification; Co. Given Time Till May 11, 2026 To Regain Compliance
📉 NegativeBenzinga•Nov 14, 2025, 09:32 PM
IceCure Medical Promotes Shay Levav To COO, As Company Expands Commercial Activities In U.S. Following FDA Marketing Clearance For ProSense
📈 PositiveBenzinga•Nov 10, 2025, 01:42 PM
IceCure Announces Publication Of Independent Study Using Co.'s Cryoablation System Showing 5-Year Overall Survival For Stereotactic Body Radiation Therapy Followed By Cryoablation Was 74%
📈 PositiveBenzinga•Nov 3, 2025, 01:38 PM
HC Wainwright & Co. Maintains Buy on Icecure Medical, Raises Price Target to $2.5
📈 PositiveBenzinga•Oct 7, 2025, 10:44 AM
IceCure Medical Shares Resume Trade
➖ NeutralBenzinga•Oct 3, 2025, 04:51 PM
Trading Halt: Halt status updated at 12:45:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 3, 2025, 04:45 PM
FDA Grants Marketing Authorization To IceCure's De Novo Application For ProSense Cryoablation System For Local Treatment Of Breast Cancer
📈 PositiveBenzinga•Oct 3, 2025, 04:22 PM
Trading Halt: Halted at 9:52:47 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 3, 2025, 01:55 PM
IceCure Showcases Cryoablation Advances At EUSOBI 2025; Full-Capacity Workshop, 5 ProSense Abstracts Presented, And Grant Award For Imaging Biomarker Study
📈 PositiveBenzinga•Sep 30, 2025, 12:49 PM
IceCure Showcases ProSense Cryoablation With Key Studies And Training At The Cardiovascular And Interventional Radiology Society Of Europe Annual Meeting On September 13-17, 2025
📈 PositiveBenzinga•Sep 22, 2025, 12:34 PM
IceCure Medical Receives U.S. Patent Approval For New Cryoprobe Invention Aimed At Safer Tumor Extraction
📈 PositiveBenzinga•Sep 18, 2025, 12:38 PM
IceCure Granted Notice Of Allowance For US Patent For XSense Cryoprobes
📈 PositiveBenzinga•Sep 18, 2025, 12:36 PM
IceCure Receives Approval From Medical Device Division Of Israel's Ministry Of Health For Its XSense Cryoablation System For Breast Cancer And Other Indications
📈 PositiveBenzinga•Sep 15, 2025, 12:31 PM
IceCure Medical's ProSense Cryoablation Shows High Patient Satisfaction And Best Ablation Rates In Studies Published In European Journal Of Surgical Oncology And Radiology
📈 PositiveBenzinga•Sep 8, 2025, 12:36 PM
Frequently Asked Questions about ICCM
What is ICCM's current stock price?
IceCure Medical Ltd (ICCM) is currently trading at $0.67 per share. The stock has moved +1.92% today.
What is the analyst price target for ICCM?
The average analyst price target for ICCM is $2.38, based on 1 analyst.
What sector is IceCure Medical Ltd in?
IceCure Medical Ltd operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is ICCM's market cap?
IceCure Medical Ltd has a market capitalization of $0.05 billion, making it a small-cap company.
Does ICCM pay dividends?
No, IceCure Medical Ltd does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBDMD
Baird Medical Investment Holdings Limited
$1.39
Mkt Cap: $0.1B
CTSO
Cytosorbents Corporation
$0.64
Mkt Cap: $0.0B
ECOR
electroCore, Inc.
$4.60
Mkt Cap: $0.0B
MDAI
Spectral AI, Inc.
$1.55
Mkt Cap: $0.0B
MDCX
Medicus Pharma Ltd. Common Stock
$1.69
Mkt Cap: $0.0B
PETS
PetMed Express, Inc.
$3.60
Mkt Cap: $0.1B
SRTS
Sensus Healthcare, Inc.
$3.83
Mkt Cap: $0.1B
TELA
TELA Bio, Inc.
$1.13
Mkt Cap: $0.0B
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$1.41
Mkt Cap: $0.0B
VNRX
VolitionRx Limited
$0.26
Mkt Cap: $0.0B
Explore stocks similar to ICCM for comparison